DOCSLIB.ORG

Important Note:All Human Products Must Be Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

* Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME Qty 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1Aa Digtalis glycoside 02-01-00001 digoxin tab 62.5 mcg 800,000 02-01-00002 digitoxin tab 100 mcg 800,000 02-01-00003 digoxin tab 125 mcg 800,000 02-01-00004 digoxin tab 250 mcg 30,415,200 02-01-00005 digoxin PG elixir 50mcg /ml 800,000 02-01-00006 digoxin inj 250 mcg/ml, (2ml amp) 800,000 1Ab PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone inj 5mg/ml (20ml amp) 800,000 1B DIURETICS 02-01-00008 amiloride Hcl 5mg + hydrochlorthiazide 50mg tab 50,000,000 02-01-00009 bumetanide tab 1 mg 1,094,000 02-01-00010 chlorthalidone tab 50mg 3,264,000 02-01-00011 ethacrynic acid as sod.salt inj powder for 800,000 reconstitution 50mg vial 02-01-00012 frusemide inj 20mg/2ml amp 5,780,400 02-01-00013 frusemide I.V. infusion inj 10mg/ml, (25ml amp) 800,000 02-01-00014 frusemide tab 40mg 25,000,000 02-01-00015 frusemide scored tab 500mg 800,000 02-01-00016 frusemide oral solution pead liquid 1mg/1ml 800,000 02-01-00017 frusemide oral solution 4mg/ml 800,000 02-01-00018 frusemide oral solution 8mg/ml 800,000 02-01-00019 hydrochlorothiazide tab 25mg 1,084,000 02-01-00020 hydrochlorothiazide tab 50mg 1,396,000 02-01-00021 indapamide tab 2.5mg 800,000 02-01-00022 Indapamide s/r coated tab 1.5mg 800,000 02-01-00023 spironolactone tab 25mg 5,568,400 02-01-00024 spironolactone tab 100mg 5,147,200 02-01-00025 Xipamide tab 20mg 800,000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 acebutolol tab 100mg 800,000 02-01-00027 acebutolol tab 200mg 800,000 02-01-00028 atenolol tab 100mg 100,000,000 02-01-00029 atenolol tab or (scored tab) 50mg 37,634,800 02-01-00030 atenolol tab 25mg 982,400 02-01-00031 Bisoprolol fumarate scored tab 5mg 800,000 02-01-00032 Bisoprolol fumarate scored tab 10mg 800,000 02-01-00033 Carvedilol 6.25mg tab 800,000 02-01-00034 Carvedilol 12.5mg tab 800,000 02-01-00035 Carvedilol 25mg tab 800,000 02-01-00036 Esmolol Hcl IV infusion 10mg/ml (10ml vial) 800,000 02-01-00037 labetalol inj 5mg/ml (20ml amp) 800,000 02-01-00038 labetalol tab 200mg 800,000 02-01-00039 labetalol tab 400mg 800,000 02-01-00040 metoprolol tab 50mg 800,000 02-01-00041 metoprolol tab (s/r) 200mg 800,000 02-01-00042 metoprolol tartrate I.V. inj 1mg/1ml (5ml amp) 800,000 1 of 151 MOH CODE ITEM NAME Qty 02-01-00043 metoprolol tartrate 100mg (CR)(ZOK) tab 800,000 02-01-00044 metoprolol tartrate 50mg (CR)(ZOK) tab 800,000 02-01-00045 nadolol tab 80mg 800,000 02-01-00046 oxprenolol Hcl tab 40mg 1,434,000 02-01-00047 pindolol tab 5mg 1,098,000 02-01-00048 propranolol Hcl slow IV inj 1mg/ml (1ml amp) 800,000 02-01-00049 propranolol Hcl tab 10mg 35,161,600 02-01-00050 propranolol Hcl tab (or scored tab) 40mg 50,000,000 02-01-00051 propranolol Hcl cap (s/r) 80mg 800,000 02-01-00052 sotalol tab 40mg 800,000 02-01-00053 sotalol tab 80mg 800,000 1D ANTI-ARRHYTHMIC DRUGS 02-01-00054 amiodarone Hcl inj 50mg/ml (3ml amp) 800,000 02-01-00055 Amiodarone Hcl tab 200mg 6,729,200 02-01-00056 bretylium tosylate inj 50mg/ml,( 10ml amp) 800,000 02-01-00057 disopyramide caps 100mg 1,963,200 02-01-00058 disopyramide tab (s/r) durules 150mg 800,000 02-01-00059 disopyramide tab retard (s/r) 250mg 800,000 02-01-00060 disopyramide inj 10mg/ml, (5ml amp) 800,000 02-01-00061 lignocaine Hcl I.V. slow infusion inj 20mg/ml, 800,000 (50ml vial) plain 02-01-00062 lignocaine Hcl 5%+dextrose 7.5% inj 800,000 02-01-00063 lignocaine Hcl 1.5%+dextrose 7.5% inj 800,000 02-01-00064 mexiletine Hcl caps 50mg 800,000 02-01-00065 mexiletine Hcl caps 200mg 2,237,200 02-01-00066 mexiletine Hcl IV,IV infusion inj 25mg/ml, (10ml 800,000 amp) 02-01-00067 phenytoin sod.inj 50mg/ml, (5ml amp) 800,000 02-01-00068 practolol inj 2mg/ml, (5ml amp) 800,000 02-01-00069 procainamide Hcl slow I.V.I.V infusion inj 800,000 100mg/ml, (10ml vial) 02-01-00070 procainamide Hcl tab 500mg 800,000 02-01-00071 procainamide Hcl tab (s/r) 750mg 800,000 02-01-00072 propafenon Hcl tab 150mg 800,000 02-01-00073 quinidine Bisulfate tab (s/r) 250mg =quinidine 800,000 sulphate 200mg (Durules) 02-01-00074 quinidine Sulphate tab 200mg 800,000 02-01-00075 verapamil Hcl inj 2.5mg/ml, (2ml amp) 800,000 02-01-00076 verapamil Hcl tab 40mg 3,545,600 02-01-00077 verapamil Hcl tab 80mg 1,080,000 02-01-00078 verapamil Hcl tab (s/r) 120mg or cap, 800,000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00079 alfuzosin Hcl tab 2.5mg 882,000 02-01-00080 alfuzosin Hcl (S/R) tab 5mg 1,124,000 02-01-00081 captopril tab 25mg 100,000,000 02-01-00082 captopril tab 50mg 65,000,000 02-01-00083 captopril tab 12.5mg 800,000 02-01-00084 Candesartan cilexetil scored tab 8mg 800,000 02-01-00085 clonidine Hcl 50mcg tab 800,000 02-01-00086 clonidine Hcl 75mcg tab 800,000 02-01-00087 clonidine Hcl TTS2 (skin pactch ) (transdermal 800,000 therapy system) 0.2mg/ day 02-01-00088 diazoxide tab 50mg 800,000 02-01-00089 doxazosin scored tab 2mg 1,098,800 02-01-00090 doxazosin mesylate tab 1mg 800,000 02-01-00091 doxazosin mesylate tab 2mg 800,000 2 of 151 MOH CODE ITEM NAME Qty 02-01-00092 enalapril maleate scored tab 5mg 800,000 02-01-00093 enalapril maleate scored tab 10mg 800,000 02-01-00094 enalapril maleate scored tab 20mg 820,000 02-01-00095 hydralazine Hcl I.V. infusion inj 20mg per amp 800,000 02-01-00096 hydralazine Hcl tab 25mg 800,000 02-01-00097 hydralazine Hcl tab 50mg 800,000 02-01-00098 Lisinopril tab 5mg 800,000 02-01-00099 Lisinopril tab 10mg 956,400 02-01-00100 Lisinopril tab 20mg 800,000 02-01-00101 Losartan potassium tab 50mg 800,000 02-01-00102 Irbesartan 150mg tab 800,000 02-01-00103 Irbesartan 300mg tab 800,000 02-01-00104 methyldopa inj 50mg/ml, (5ml amp) 800,000 02-01-00105 methyldopa tab 250mg 50,000,000 02-01-00106 minoxidil tab 5mg 800,000 02-01-00107 minoxidil tab 10mg 800,000 02-01-00108 Perindopril Tert-butylamine erbumine 2mg tab 800,000 02-01-00109 Perindopril Tert-butylamine erbumine 4mg tab 800,000 02-01-00110 phenoxybenzamine Hcl caps 10mg 12,252,000 02-01-00111 phenoxybenzamine Hcl inj 50mg/ml, (2ml amp) 800,000 02-01-00112 phentolamine mesylate inj 10mg/ml, (1ml amp) 800,000 02-01-00113 prazosin Hcl tab 0.5mg 800,000 02-01-00114 prazosin Hcl tab or scored tab 1mg 800,000 02-01-00115 prazosin Hcl tab 2mg 800,000 02-01-00116 prazosin Hcl tab 5mg 800,000 02-01-00117 Quinapril Hcl tab 5mg 800,000 02-01-00118 Quinapril Hcl tab 10mg 800,000 02-01-00119 Quinapril Hcl tab 20mg 800,000 02-01-00120 Ramipril scored tab or cap: 2.5mg 800,000 02-01-00121 Ramipril scored tab or cap: 5mg 800,000 02-01-00122 Ramipril scored tab or cap: 10mg 800,000 02-01-00123 Ramipril cap: 1.25mg 800,000 02-01-00124 reserpine tab 100mcg 800,000 02-01-00125 Sodium nitroprusside I.V. infusion 50mg Amp with 800,000 solvent or Sod.nitroprusside infusion inj 30mg/ amp with solvent 02-01-00126 tolazoline Hcl inj i.v 800,000 02-01-00127 Valsartan cap 160mg 1,708,800 02-01-00128 Valsartan cap 40mg 800,000 02-01-00129 Valsartan cap 80mg 800,000 02-01-00130 Telmisartan 40mg tab 800,000 02-01-00131 Telmisartan 80mg tab 800,000 1F VASODILATORS 02-01-00132 Amlodipine (as besylate) tab 2.5mg 800,000 02-01-00133 Amlodipine (as besylate) scored tab 5mg 800,000 02-01-00134 Amlodipine (as besylate) scored tab 10mg 800,000 02-01-00135 cinnarizine tab 25mg 25,000,000 02-01-00136 cinnarizine cap or tab 75mg 3,017,200 02-01-00137 diltiazem Hcl cap or tab 60mg normal release 22,950,400 02-01-00138 diltiazem Hcl cap or tab (s/r) 90mg 13,283,600 02-01-00139 diltiazem Hcl cap or tab (s/r) 120mg 9,529,200 02-01-00140 diltiazem Hcl cap or tab (s/r) 180mg 800,000 02-01-00141 diltiazem Hcl cap or tab (s/r) 240mg or 200mg 800,000 02-01-00142 diltiazem Hcl cap or tab (s/r) 300mg 800,000 02-01-00143 Felodipine 5mg tab 800,000 3 of 151 MOH CODE ITEM NAME Qty 02-01-00144 glyceryl trinitrate tab 0. 5mg 60,000,000 02-01-00145 glyceryl trinitrate inj 5mg/10ml amp.
Recommended publications
  • R&D UNICANCER Annual Report 2016

    R&D UNICANCER Annual Report 2016

    Going further, innovating together R&D UNICANCER Annual Report 2016 Summary Presentation and organisation Regulatory affairs, pharmaco- PAGE 01 vigilance, quality assurance – Ensuring quality and safety 2016 clinical activity in clinical trials. PAGE 08 PAGE 25 Expert groups Epidemiological Strategy and PAGE 16 Medical Economics (ESME) 2016 publications Programme – Harnessing PAGE 21 real-life data in oncology to improve patient care. Clinical operations PAGE 27 PAGE 23 Development Biological Resource and partnerships – Centre (BRC) Optimising collaborations PAGE 24 to foster innovation PAGE 30 Research in the FCCC PAGE 32 Appendices PAGE 33 Contacts, Follow us PAGE 45 GOING FURTHER, INNOVATING TOGETHER R&D ANNUAL REPORT 2016 Presentation and organisation UNICANCER, a major French player in oncology, Acteur majeur de la cancérologie française, groups together 20 French Comprehensive Cancer UNICANCER regroupe les 20 Centres de lutte contre Centers (FCCC). They are private, non-profit health la cancérologie (CLCC), établissements de santé establishments exclusively dedicated to care, research privés à but non lucratif exclusivement dédiés aux and education in cancer. UNICANCER’s R&D soins, à la recherche et à l’enseignement en cancéro- department is the driving force of UNICANCER’s logie. R&D UNICANCER en tant que promoteur research and, as an academic sponsor, it works direc- aca démi que, travaille en direct avec les unités de tly with the research units of the FCCC and other recherche des CLCC et d’autres établissements health establishments (university hospitals, hospitals de santé (CHU, CH, cliniques) en France et à l’inter- and clinics) in France and abroad. The mission of R&D national.
  • WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT

    WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT (51) International Patent Classification: Published: C07D 413/14 (2006.01) A61K 31/553 (2006.01) — with international search report (Art. 21(3)) C07D 403/14 (2006.01) A61P 35/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/040866 amendments (Rule 48.2(h)) (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,001 06 July 2016 (06.07.2016) 62/454,163 03 February 2017 (03.02.2017) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Tran s fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: ROSS, Brian, D.; 2410 Foxway, Ann Arbor, MI 48105 (US). VAN DORT, Marcian; 643 Dornoch Dr., Ann Arbor, MI 48103 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • Appendix on Tariff Elimination Schedule for Mercosur

    Appendix on Tariff Elimination Schedule for Mercosur

    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
  • Rediscovery of Fexinidazole

    Rediscovery of Fexinidazole

    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste

    NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste

    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Pp-03-25-New Dots.Qxd 10/23/02 2:38 PM Page 379

    Pp-03-25-New Dots.Qxd 10/23/02 2:38 PM Page 379

    pp-03-25-new dots.qxd 10/23/02 2:38 PM Page 379 HYDROGEN SULFIDE 379 HYDROGEN SULFIDE [7783-06-4] Formula: H2S; MW 34.08 Synonyms: sulfur hydride; sulfureted hydrogen Occurrence and Uses Hydrogen sulfide occurs in natural gas. It also is found in many sewer gases. It is a by-product of many industrial processes. Trace amounts of dis- solved H2S are found in wastewaters in equilibrium with dissolved sulfides and hydrosulfides. It also is found in volcanic eruptions, hot springs and in troposphere. The average concentration of H2S in the air is about 0.05 ppb. The most important applications of hydrogen sulfide involve the production of sodium sulfide and other inorganic sulfides. Hydrogen sulfide obtained as a by-product often is converted into sulfuric acid. It also is used in organic syn- thesis to make thiols or mercaptans. Other applications are in metallurgy for extracting nickel, copper, and cobalt as sulfides from their minerals; and in classical qualitative analytical methods for precipitation of many metals (see Reactions). It also is used in producing heavy water for nuclear reactors. Physical Properties Colorless gas; characteristic odor of rotten eggs; odor threshold 1ppm; sweetish taste; fumes in air; flammable gas, burns with a pale blue flame; refractive index at 589.3nm, 1.000644 at 0°C and 1 atm; density 1.539 g/L at 0°C; critical temperature 100.4°C; critical pressure 88.9 atm; liquefies at –60.7°C; solidifies at –85.5°C; velocity of sound 289 m/sec in H2S gas; slightly soluble in water (0.4% at 20°C); pH of a saturated aqueous solution 4.5; slight- ly acidic; diffusivity in water at 16°C, 1.77x105 cm2/sec; soluble in carbon disulfide, methanol, acetone; very soluble in N-methylpyrrolidinone and alka- nolamines (salt formation occurs: salt dissociates on heating); liquid H2S dis- solves sulfur and SO2.
  • Vitiligo Treatment

    Vitiligo Treatment

    ISSN 2320-5407 International Journal of Advanced Research (2014) Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH Depigmentation Therapy for Vitiligo: Results from a National Survey Dissertation submitted to Libyan International Medical University In partial fulfillment of the requirements For the award of the degree of Bachelor of Pharmacy BY Makpula Abdelaziz Tarhuni Aisha Ali Derbash Under The Guidance of Dr. Salma Bukhatwa 1 ISSN 2320-5407 International Journal of Advanced Research (2014) Declaration This is to certify that research work embodied in this thesis entitled "Depigmentation therapy of vitiligo: Results from a national survey" has been carried out by us under supervision of Dr. Salma Bukhatwa. Makpula Abdelaziz Tarhuni ................................................... Aisha Ali Derbash ...................................................... 2 ISSN 2320-5407 International Journal of Advanced Research (2014) Abstract Vitiligo is a chronicpigmentarydisorderthat causes the loss of skin color in blotches. Vitiligo happens because of destruction of melanocytes. Classification of vitiligo according to distribution of the lesions is of practical importance usually for assessing the prognosis of the disease. Repigmentation therapyfor vitiligo includes corticosteroids, topical and oral antioxidants, topical calcineurin inhibitors, phototherapy and laser therapy. Depigmentation therapy can be beneficial as alternative therapy for extensive vitiligo patients. Depigmentation therapyof vitiligo